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Abstract
Background: HIV-1 infects macrophages and microglia in the brain and can cause neurological disorders in infected
patients. We and others have shown that brain-derived envelope glycoproteins (Env) have lower CD4 dependence and
higher avidity for CD4 than those from peripheral isolates, and we have also observed increased fusogenicity and reduced
sensitivity to the fusion inhibitor T-1249. Due to the genetic differences between brain and spleen env from one individual
throughout gp120 and in gp41's heptad repeat 2 (HR2), we investigated the viral determinants for the phenotypic
differences by performing functional studies with chimeric and mutant Env.
Results: Chimeric Env showed that the V1/V2-C2-V3 region in brain's gp120 determines the low CD4 dependence and
high avidity for CD4, as well as macrophage tropism and reduced sensitivity to the small molecule BMS-378806. Changes
in brain gp41's HR2 region did not contribute to the increased fusogenicity or to the reduced sensitivity to T-1249, since
a T-1249-based peptide containing residues found in brain's but not in spleen's HR2 had similar potency than T-1249 and
interacted similarly with an immobilized heptad repeat 1-derived peptide in surface plasmon resonance analysis.
However, the increased fusogenicity and reduced T-1249 sensitivity of brain and certain chimeric Env mostly correlated
with the low CD4 dependence and high avidity for CD4 determined by brain's V1-V3 region. Remarkably, most but not
all of these low CD4-dependent, macrophage tropic envelopes glycoproteins also had increased sensitivity to the novel
allosteric entry inhibitor HNG-105. The gp120's C2 region asparagine 283 (N283) has been previously associated with
macrophage tropism, brain infection, lower CD4 dependence and higher CD4 affinity. Therefore, we introduced the
N283T mutation into an env clone from a brain-derived isolate and into a brain tissue-derived env clone, and the T283N
change into a spleen-derived env from the same individual; however, we found that their phenotypes were not affected.
Conclusion: We have identified that the V1-V3 region of a brain-derived envelope glycoprotein seems to play a crucial
role in determining not only the low CD4 dependence and increased macrophage tropism, but also the augmented
fusogenicity and reduced sensitivity to T-1249 and BMS-378806. By contrast, increased sensitivity to HNG-105 mostly
correlated with low CD4 dependence and macrophage tropism but was not determined by the presence of the brain's
V1-V3 region, confirming that viral determinants of phenotypic changes in brain-derived envelope glycoproteins are likely
complex and context-dependent.
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Background
Human immunodeficiency virus type 1 (HIV-1) envelope
glycoproteins (Env), the heavily glycosylated surface
gp120 and the non-covalently associated transmembrane
subunit gp41, are organized on the virion surface as
trimeric spikes and mediate viral entry into susceptible
cells. The surface gp120 is composed of a core of con-
served regions (C1-C5), shielded by variable loop regions
(V1-V5) formed by disulfide bonds (except V5) that retain
a large degree of flexibility. The gp41 ectodomain (gp41e)
contains the fusion peptide, which is inserted into the
membrane of the target cells, as well as two heptad repeat
(HR) domains (amino-terminal or HR1 and carboxy-ter-
minal or HR2) that are involved in the formation of a
fusion intermediate, the six-helix bundle, through confor-
mational rearrangements following receptor interaction.
HIV-1 infection requires two sequential and specific bind-
ing steps: first, to the CD4 antigen present in CD4+ T-cells,
monocyte/macrophages and other cells; and second, to a
member of the chemokine receptor subfamily, within the
G protein-coupled, seven-transmembrane domain family
of receptors, mainly CCR5 and/or CXCR4.
Structural analysis of unliganded gp120 from the related
simian immunodeficiency virus has suggested that the
large gp120 region involved in binding to CD4, the CD4-
binding site (CD4bs), may only form a stable, binding-
competent conformation when gp120 actually engages
CD4 [1]. The interaction with CD4 triggers a rather large
conformational change in gp120 that results in the forma-
tion and/or exposure of highly conserved regions previ-
ously folded into the core structure and/or sheltered by
the variable loops and the glycans covering the outer
domain of gp120 [2-9]. These CD4-induced regions con-
tain discontinuous structures that react with certain
human neutralizing monoclonal antibodies (mAbs) (e.g.,
17b), which inhibit chemokine receptor binding to gp120
[2,5,7-15], and therefore constitute a high-affinity bind-
ing site for the co-receptor molecule. Chemokine receptor
binding by gp120 has been suggested to occur first
through the amino terminus, which then allows interac-
tion with the second extracellular loop, and subsequently
triggers further conformational changes on gp120 that are
transduced to gp41 and lead to the fusion-active confor-
mation of HIV-1 Env [16-21] and the formation of a
fusion pore.
HIV-1 infection of the central nervous system (CNS)
seems to occur early after primary infection. Subse-
quently, HIV-1-infected individuals may develop a neuro-
logical syndrome ranging from the mild minor cognitive/
motor disorder to HIV-associated dementia, although sig-
nificant neurological dysfunction and neurodegeneration
are typical in advanced stages of disease [22]. Although
anti-retroviral therapy has decreased the incidence of HIV-
associated dementia, neurological abnormalities continue
to be a relevant problem among all HIV-positive individ-
uals [22,23]. HIV-1 likely enters the CNS as cargo in virus-
infected monocytes migrating into the brain to replenish
the population of perivascular macrophages. Accordingly,
perivascular macrophages and microglia (long-lived,
brain resident macrophages) seem to be responsible for
most of the viral production within the brain. Multinucle-
ated giant cells, the end product of fusion between
infected and uninfected cells, are the principal neu-
ropathological finding of HIV-1 infection in the brain and
hallmark of HIV-1 encephalitis [24-27].
Microglia and perivascular macrophages may survive for
long time after infection. They express CCR5, CXCR4 and
some minor co-receptors [28], but similarly to macro-
phages from other tissues, CD4 expression is either unde-
tectable or very low [29-32]. Hence, the nature of the
infected cells and the special immunological status of the
brain may allow viral persistence and replication in the
brain. Several studies have described that viruses isolated
from the brain display macrophage tropism and mainly
use CCR5 to infect microglia [33-38], suggesting that viral
tropism for microglia and macrophages may be deter-
mined by similar mechanisms [39-41]. In addition,
numerous studies support that HIV-1 evolve independ-
ently within the CNS and in particular the brain [42-48]
probably leading to compartmentalization and a progres-
sive adaptation to this niche.
We previously described that a primary peripheral isolate
adapted in vitro to grow in pure human adult microglial
cultures developed increased fusogenicity and an
improved ability to use low levels of CD4 on the target cell
membrane for fusion and infection (low CD4 depend-
ence) [49-51], which correlated with higher avidity and
affinity in the interaction with CD4 [52]. The phenotypic
changes mapped to the envelope glycoproteins, which dif-
fered only in 8 amino acids, and specifically to four amino
acid changes in the V1/V2 region of gp120, which proba-
bly result in a more open or partially-triggered gp120 con-
formation. Subsequently, we hypothesized that HIV-1
could adapt within the brain compartment to specifically
improve its ability to use low levels of CD4 for entry/
infection on target cells, and therefore viruses with low
CD4 dependence and high CD4 affinity might be natu-
rally selected in vivo in the CNS of HIV-1-infected individ-
uals.
We and others have investigated whether viruses or Env
with these particular phenotypes are present among pri-
mary isolates in the brain/CNS of HIV-1-infected individ-
uals [35,44,53-57]. In this sense, Peters et al. have
reported that the macrophage tropism of brain-derived
Env seems to correlate with reduced sensitivity to inhibi-Retrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
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tion by an anti-CD4 mAb but not by CCR5 antagonists or
gp41-targeting antibodies or fusion inhibitor peptides
[55,56]. Thomas et al. have also recently reported that effi-
cient entry into macrophages is more frequent among Env
from brain than from lymphoid tissues and seems to cor-
relate with both low CD4 dependence and overall effi-
ciency of fusion [57]. In addition, Dunfee et al. found that
asparagine in position 283 (N283) in gp120's C2 region
seems to be more common in Env from brain than from
lymphoid tissues, associates with the presence of demen-
tia and could contribute to the lower CD4 dependence,
slightly increased affinity for CD4 and enhanced macro-
phage tropism [53]. Likewise, we have previously reported
that Env derived from the brain of an individual with HIV-
1 encephalitis have lower CD4 dependence and higher
avidity for CD4, mediate increased fusion and have signif-
icantly lower sensitivity to the fusion inhibitor T-1249,
than spleen-derived Env from the same subject [54]. These
envelope glycoproteins differed in numerous amino acid
residues throughout gp120, with many changes clustering
in or around the variable regions V1/V2 and V3, and in the
HR2 region of gp41e, but not in HR1.
Several early studies identified the V3 region in gp120 as
a primary determinant of macrophage tropism in enve-
lope glycoproteins from CCR5-using peripheral isolates
[58-63], although other gp120 regions, and especially the
V1/V2 variable loop, have also been shown to influence
the ability of viral isolates to infect macrophages [61,63-
67]. Therefore, in this study we investigated the viral
determinants for the phenotypic differences observed
between the brain- and spleen-derived Env reported
above [54], through the generation of chimeric and
mutant Env and their characterization using cell-to-cell
fusion and pseudotype infection assays. We found that
chimeric Env containing the V1-V3 region of the brain-
derived gp120 not only displayed increased macrophage
tropism but also had significantly lower CD4 dependence,
higher fusogenicity and lower sensitivity to the T-1249
fusion inhibitor and BMS-378806. Interestingly, most low
CD4-dependent, macrophage-tropic Env also showed
increased sensitivity to a novel allosteric entry inhibitor,
the short peptide HNG-105. In addition, we found similar
phenotypes with the Env from a brain-derived isolate and
obtained evidence that the role that specific amino acid
residues in gp120 play on these phenotypes is highly
dependent on the Env background.
Materials and methods
Cells
Human embryonic kidney 293T cells and quail fibrob-
lasts QT6 cells were cultured in Dulbecco's modified
Eagle's medium (DMEM; MediaTech, Hendon, VA) sup-
plemented with 10% heat-inactivated fetal bovine serum
(FBS; Clontech, Mountain View, CA) and antibiotics.
Human osteosarcoma cells (HOS) stably expressing
human CD4 and CCR5 molecules (obtained through the
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH [ARRRP], from Dr. Nathaniel
Landau) [68,69] were maintained in DMEM supple-
mented with 10% FBS, puromycin (1 μg/ml), mycophe-
nolic acid (40 μg/ml), xanthine (250 μg/ml) and
hypoxanthine (13.5 μg/ml). Human astroglioma U87
cells stably transfected for the expression of human CD4
and CXCR4 (obtained through the ARRRP from Drs.
HongKui Deng and Dan Littman) [70] were cultured in
DMEM supplemented with 10% FBS, puromycin (1 μg/
ml) and G418 (300 μg/ml) (Invitrogen-Gibco, Carlsbad,
CA).
Normal human monocytes were purchased as single cell
suspension from the Human Immunology Core of the
University of Pennsylvania Cancer Center, counted and
plated for differentiation into macrophages by culturing
at a density of 2.0 × 104 cells/well in 96-well plates for 7–
10 days in DMEM supplemented with 5% FBS and 5%
giant cell tumor conditioned media (BioVeris, Gaithers-
burg, MD), as previously described [71].
Construction of chimeric and mutant envelope 
glycoproteins
The generation and characterization of full-length, func-
tional env genes derived from brain (BR) and spleen (SPL)
autopsy tissues of an HIV-1-infected individual with
encephalitis and HIV-associated dementia (H0002GH)
was previously described [54]. Subsequently, XhoI (in
multiple cloning site of pcDNA3.1)-EcoNI fragments con-
taining most of the gp120 coding regions from BR and
SPL Env expression vectors were exchanged to construct
the BS and SB chimeric Env, which express brain-derived
gp120 with the spleen gp41 and the spleen gp120 with
the brain gp41, respectively (Figure 1). Similar to the par-
ent Env, these chimeras were functional in cell-to-cell
fusion assays but did not efficiently mediate production
of Env-pseudotyped viruses. Therefore, in order to achieve
successful production of pseudotype viruses for infection
experiments, we utilized the pHXB2-env vector (obtained
through the ARRRP from Drs. Kathleen Page and Dan Litt-
man) [72] in which highly efficient Env expression is
obtained from an SV40 promoter, and Acc65I-BsoBI frag-
ments containing a majority of the gp160 region (except
the first 11 amino acids in gp120 after the signal peptide
and the last 132 amino acids in gp41, all in the cytoplas-
mic tail and identical between the BR and SPL Env) from
the BR, SPL, BS and SB Env expression vectors in
pcDNA3.1 were sub-cloned into the pHXB2-env digested
with the same restriction endonucleases to generate pSV-
BR, -SPL, -BS, and -SB. All constructs were tested with a set
of restriction endonucleases that either cut or do not cut
the brain and spleen-derived gp120 and gp41 to confirmRetrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
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the identity of the gp120 and gp41 expressed from each
construct. Furthermore, chimeric Env containing the
brain V1/V2-C2-V3 or only the V1/V2 gp120 fragments in
the context of the spleen Env (named Bv1v3 and Bv1v2,
respectively) and the spleen V1/V2-C2-V3 or only the V1/
V2 gp120 fragments in the context of the brain Env
(named Sv1v3 and Sv1v2, respectively) were constructed
by exchanging XhoI-Bsu36I and XhoI-PvuII fragments of
BR and SPL parental Env in pcDNA3.1, and these were
subsequently sub-cloned into the corresponding pSV-BR
or pSV-SPL using Acc65I and BsoBI to generate pSV-Bv1v3,
pSV-Bv1v2, pSV-Sv1v3 and pSV-Sv1v2 (Figure 1).
To evaluate the role of N283 in various Env backgrounds,
the Env mutants pSV-BR(N283T) and pSV-SPL(T283N)
where the N283 present in the brain Env was mutated to
T and the T283 present in the spleen Env was mutated to
N, respectively, were created using QuikChange site-
directed mutagenesis (Stratagene, La Jolla, CA) following
manufacturer's instructions. The presence of the intended
mutations was verified by sequence analysis.
Finally, we also characterized several Env from the HIV-
1DS-br isolate, recovered from an adult AIDS patients with
dementia by Dr. Suzanne Gartner (Johns Hopkins Univer-
sity) through co-cultivation of brain tissue with mono-
cyte-derived macrophages (MDM) [73,74]. Human adult
microglial cells were previously infected with this viral
isolate and total DNA was isolated 3 days post-infection
and used for env amplification [38]. We have now fully
sequenced these env  clones (named DS12, DS13 and
DS17) (kindly provided by Dr. Francisco González-Scar-
ano, University of Pennsylvania) (GenBank accession
numbers, EU850429–EU850431) and used them for phe-
notypic analyses to determine whether the Env pheno-
types are similar to those identified in env  amplified
directly from brain tissue of HIV-1-infected individuals. In
addition, we have used QuikChange site-directed muta-
genesis to generate the Env mutant DS17(N283T), in
which the N283 residue present in the DS17 clone was
mutated to T. The mutation was verified by sequence anal-
ysis.
Peptides and other reagents
Fusion inhibitors T-20 (YTSLIHSLIEESQNQQEKNEQEL-
LELDKWASLWNWF) and the more potent T-1249
(WQEWEQKITALLEQAQIQQEKNEYELQKLDK-
WASLWEWF) are based on the sequence of the HR2
region of gp41e from the HIV-1HxB isolate and inhibit viral
entry by targeting the envelope glycoproteins at a fusion
intermediate state [75,76]. T-20 and T-1249, as well as the
derived peptides T-20-BR (YTNLIYNLIEKSQN-
Schematic representation of chimeric and mutant Env Figure 1
Schematic representation of chimeric and mutant Env. Chimeric Env constructs between brain- and spleen-derived 
Env of one individual were made to map the viral determinants of phenotypic changes. Single mutants were constructed to test 
for the role of N283 and T283 on the phenotypes observed.
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QQEMNEQELLKLDTWASLWNWF) and T-1249-BR
(WQEWEQKITALLEQAQIQQEMNEQELQKLDT-
WASLWEWF) that contain amino acid changes (shown in
bold) present in the HR2 region of the previously charac-
terized H0002GH brain-derived env clones [54], were cus-
tom synthesized (BioSynthesis, Inc., Lewisville, TX). In
addition, a biotinylated, HR1-derived peptide (N40,
biotin-RQLLSGIVQQQNNLLRAIEAQQHL-
LQLTVWGIKQLQARVL) and a biotinylated scramble pep-
tide (N40scr), to be used as negative control in biosensor
experiments, were also custom synthesized. All peptides
were dissolved to 1–2 mg/ml final concentration in 10–
25% DMSO, aliquoted and stored at -80°C until use. The
desired dilutions for inhibition or interaction experiments
were freshly made in DMEM or phosphate-buffered saline
(PBS), respectively.
The gp120-targeted small molecule BMS-378806 [77,78],
a gift from Dr. Amos Smith (University of Pennsylvania),
is an entry inhibitor that has been proposed to function
through inhibition of CD4 binding [79,80]; however,
other evidences indicate that it may bind to unliganded
gp120 and target the CD4-induced conformational re-
arrangement of gp120 and gp41 [81,82]. The 12p1-
derived short peptide HNG-105 (kindly provided by Drs.
Hosahudya Gopi and Irwin Chaiken, Drexel University
College of Medicine) was generated by click conjugation
and functions as an entry inhibitor since it prevents viral
infection and has been shown to inhibit interactions of
both monomeric and trimeric soluble gp120 with soluble
CD4 [83-86]. It has been suggested that HNG-105 works
through a novel allosteric mechanism, interacting with a
site different from the CD4 or co-receptor binding sites
but resulting in a lower affinity of gp120 for either of its
receptors. The SK3 anti CD4 mAb was purchased from
Becton Dickinson (San Jose, CA).
Pseudotype production and infections
To produce Env-pseudotyped, luciferase-reporter viruses,
293T cells were co-transfected using calcium phosphate
precipitation (ProFection Mammalian Transfection Sys-
tem, Promega, Madison, WI) with each Env expression
vector and with the Env-deficient, pNL4-3-luc+env- provi-
rus, developed by N. Landau by introducing a frameshift
mutation in the env  gene of pNL4-3-luc+ [87]. Culture
supernatants containing the pseudotyped particles were
collected 48–72 hours after transfection, clarified by cen-
trifugation, aliquoted and stored at -80°C until use. Pseu-
dotype particles lacking envelope glycoproteins, which
are generated by co-transfecting the luciferase HIV-1 pro-
viral backbone with an empty expression vector, are used
as negative control for all pseudotype infections. Pseudo-
type stocks were quantitated using a p24gag antigen cap-
ture ELISA (SAIC-National Cancer Institute) and
normalized amounts of stocks were used to infect target
cells for 5–6 hours at 37°C. At 2–3 days post-infection,
the cells were washed with PBS and lysed, and the amount
of entry mediated by each Env was measured by detecting
luciferase activity (Luciferase Assay System, Promega) in a
microplate luminometer (GloMax, Promega), following
manufacturer's instructions. Results are obtained as rela-
tive light units (RLU) per second. At least three independ-
ent experiments were performed for each analysis
described below, with 2–8 replicates within each experi-
ment.
To test for CD4 and CCR5 dependencies, QT6 cells were
transfected with 5 or 0.5 μg DNA (per 106 cells) of the cor-
responding expression vectors, since it has been shown
that these amounts result in either high or low receptor
expression levels, respectively, in the cell surface [54].
Empty pcDNA3.1 vector was used to equal the total
amount of DNA used per well. After transfection, target
cells were collected with Versene (Invitrogen), re-plated
into 96-well plates and incubated overnight before infec-
tion.
To investigate the avidity of the interaction between Env
trimers in the surface of viral particles and CD4 in the tar-
get cell membrane, HOS-CD4-CCR5 cells plated in 96-
well plates 24 hours before infection, were incubated for
30–60 minutes at 4°C with 2× the final concentration of
SK3 anti-CD4 mAb in a volume of 50 μl; subsequently, 50
μl of viral pseudotype stocks were added and the cells
were incubated for 5–6 hours at 37°C before removing
the inoculum, washing with PBS and incubating for 2–3
days.
To test for sensitivity to fusion inhibitors, BMS-378806
and HNG-105, the medium from HOS-CD4-CCR5 cells
plated in 96-well plates 24 hours before infection, was
removed and replaced by fresh medium containing 2× the
final concentration of the corresponding inhibitor, and
immediately the same volume of viral stocks was added.
After 5–6 hours at 37°C, inocula and inhibitors were
removed and the cells were incubated for 2–3 days before
evaluating the amount of infection.
Finally, macrophage tropism was determined by infecting
in parallel MDMs and HOS-CD4-CCR5 cells. After 2–3
days, the extent of infection was measured by testing for
luciferase activity in cell lysates (Luciferase Assay System,
Promega).
Env-mediated cell-to-cell fusion assays
Cell-to-cell fusion assays were used to test for fusogenicity,
receptor utilization and sensitivity to inhibitors. Briefly,
106  QT6 effector cells per well in 6-well plates were
infected at a multiplicity of infection of 2 with the recom-
binant vaccinia virus vTF1.1 that expresses the bacteri-Retrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
Page 6 of 22
(page number not for citation purposes)
ophage T7 RNA polymerase [88] for 1–2 hours at 37°C.
After removing the inoculum and washing with PBS,
DMEM supplemented with rifampicin was added and the
cells were subsequently transfected by calcium phosphate
precipitation with an Env expression vector (or empty
pcDNA3.1 as a negative control). After 4 hours at 37°C,
the cells were washed, DMEM with rifampicin was added,
and the cells were incubated overnight at 32°C. Concur-
rently, 106 QT6 target cells per well in 6-well plates were
transiently transfected with 5 μg DNA of each CD4 and
CCR5 expression vectors, or CD4 plus empty vector as
negative control, and 3 μg of pT7-luc, a luciferase-expres-
sion vector where the firefly luciferase gene is under the
control of the T7 promoter, for 5 hours at 37°C. DNA was
then removed, and cells were collected with Versene and
re-plated into 96-well plates and incubated at 37°C over-
night. The next day, effector cells were collected, overlaid
onto target cells, and incubated at 37°C for 5–6 hours (for
receptor utilization and inhibition experiments), or for
various time periods between 30 minutes and 7 hours (for
fusogenicity experiments). Luciferase activity (indicative
of fusion) was measured in cell lysates as described above.
At least two independent experiments were performed for
testing the sensitivity to the SK3 anti-CD4 mAb, the T-
1249 and T-1249-BR fusion inhibitors and the small mol-
ecule BMS-378806, with samples at least in triplicate
within each experiment. Results were obtained as RLU per
second.
Optical biosensor binding experiments
Interaction analyses were performed on a Biacore® 3000
optical biosensor (GEHC, Biacore, Piscataway, NJ) with
simultaneous monitoring of four flow cells. Immobiliza-
tion of the HR1-based peptides N40 and N40scr (a scram-
ble peptide to be used as negative control that was
generated at http://us.expasy.org/tools/randseq.html)
was achieved through interaction of an amino-terminus
biotin molecule on the peptides with the streptavidin-
coated SA sensor chips (GEHC, Biacore) following stand-
ard protocols. The N40scr surface served as a reference.
After immobilization, increasing concentrations of T-
1249 and T-1249-BR were passed over the N40 and
N40scr surfaces at 25°C using a flow rate of 25 μl min-1.
Due to the hydrophobic nature of the peptides, 8%
DMSO was included in the running buffer (25 mM Tris-
HCl, 150 mM NaCl, pH 7.4) to keep them in solution.
Regeneration of the peptide surfaces during runs was
achieved by pulses of 0.05% SDS, followed by extensive
washes of the integrated microfluidics cartridge.
Statistical analyses
Inhibition curves obtained by plotting the relative infec-
tion (expressed as a percent of untreated) versus the con-
centration of the inhibitor were analyzed by non-linear
regression with a sigmoidal dose-response model (varia-
ble slopes) using GraphPad Prism software, version 4.02
(GraphPad Software, San Diego, CA); this analysis uses a
four parameter logistic equation, Y = Bottom + (Top-Bot-
tom)/( ) where Y is the response,
Bottom is 0 and Top is 100, X is the logarithm of the con-
centration, and Slope is the slope of the curve. 50% inhib-
itory concentrations (IC50) and 95% confidence intervals
were estimated from the non-linear regression analysis.
Fusogenicity data were analyzed by non-linear regression
with a one-phase exponential model (using GraphPad
Prism) that uses the equation Y=Ymax(1-e(-kX)), where Ymax
is the maximum response and k is the observed rate. CD4
dependence data were analyzed with SPSS, version 16,
using the non-parametric Mann-Whitney test.
Results and discussion
Construction of chimeric and mutant Env
To investigate the viral determinants for the phenotypic
differences reported between the brain- and spleen-
derived Env of a patient with HIV-1 associated dementia
and encephalitis [54], we constructed chimeric env genes
as described in Materials and Methods. There were 13
amino acid differences between the wild-type BR and SPL
Env clones in V1/V2, 8 in V3 and 9 in V4, in addition to
less numerous changes in more conserved Env regions. Six
amino acid differences were also found absolutely con-
served between all brain and spleen clones from this indi-
vidual in the HR2 region of gp41e. First, we generated the
BS and SB chimeras (brain gp120-spleen gp41 and spleen
gp120-brain gp41, respectively) in pcDNA3.1 (Figure 1).
These chimeric Env were functional in cell-to-cell fusion
assays but, as with the parental wild-type Env, they did not
result in a highly efficient production of infectious pseu-
dotypes. To test whether we would be able to produce
pseudotype viruses and perform infection experiments
utilizing a different expression vector, we sub-cloned most
of the gp160 coding regions, except for the first 11 amino
acids after the signal peptide in gp120 and the last 132
amino acids in gp41 (which were identical in the brain
and spleen derived parental Env), from the BR, SPL, BS
and SB env clones in pcDNA3.1 into the pHXB2-env vec-
tor [72] in which efficient expression is obtained from an
SV40 promoter. Therefore, we generated HxB-BR, -SPL, -
BS and -SB chimeras, which will be referred to as BR, SPL,
BS and SB, respectively. Additional chimeric Env contain-
ing the brain V1/V2-C2-V3 fragment in the context of
spleen Env and vice versa (Bv1v3 and Sv1v3, respectively)
were generated, since numerous amino acid differences
between the brain and spleen Env cluster in this gp120
region, which has previously been shown to contain the
determinants for increased fusogenicity and low CD4
dependence in the Env of the in vitro microglia-adapted
11
log IC X Slope 15 +
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isolate HIV-1Bori-15 [49,50]. Furthermore, we have also
constructed chimeric Env containing only the brain-
derived V1/V2 region in the context of the spleen Env and
vice versa (Bv1v2 and Sv1v2, respectively), and we have
also generated the mutant Env SPL(T283N) and
BR(N283T) to evaluate the potential role of N283 vs.
T283 in the phenotype of these Env, as described recently
by Dunfee et al. [53].
Finally, since there is the potential that the env  genes
amplified by PCR from total DNA isolated from brain tis-
sue might not fully represent a truly replicating virus
present in that tissue, we decided to similarly characterize
several env genes obtained by PCR from microglial cells
that had been infected with HIV-1DS-br [38], a viral isolate
recovered through co-cultivation of brain tissue derived
from an adult, demented AIDS patient with normal
MDMs [73,74]; in addition, one of these clones (DS17)
was mutated to generate DS17(N283T) to test as well the
potential role of N283 in an additional Env background.
Analysis of CD4 and CCR5 dependence
First, we produced pseudotypes as indicated in Materials
and Methods and evaluated CD4 and CCR5 dependence
using target cells transiently transfected with various
amounts of the corresponding expression plasmids,
which results in the expression of low or high levels of
CD4 and CCR5, as described previously [54]. In addition,
as a surrogate for gp120:CD4 affinity, we evaluated the
inhibition of infection by the SK3 anti-CD4 mAb in HOS-
CD4-CCR5 cells that stably express very high levels of
CD4 and CCR5. As expected, the BS and SB chimeras –
containing brain gp120-spleen gp41 and spleen gp120-
brain gp41, respectively – each displayed the same pheno-
type of the corresponding wild-type BR and SPL Env, since
CD4 dependence is mostly determined by the gp120 sub-
unit. Thus, BR and BS showed greater ability to use low
levels of CD4 for infection (or lower CD4 dependence)
(Figure 2A) and reduced sensitivity to inhibition of infec-
tion by the anti-CD4 mAb (Figure 2B) than SPL and SB. In
addition, the Bv1v3 chimera and the BR(N283T) mutant
displayed a similar phenotype to BR and BS, with low
CD4 dependence and reduced sensitivity to the anti-CD4
mAb, while the phenotype of the SPL(T283N) mutant was
identical to that of SPL and SB. Finally, the Bv1v2 chimeric
Env showed an intermediate ability to use low levels of
CD4 for infection and a sensitivity to inhibition by the
anti-CD4 mAb that was closer to the wild-type parental
SPL than to the BR Env (Figure 2).
As shown in Table 1, statistical analysis of relative infec-
tion in the presence of low levels of CD4, irrespective of
the levels of CCR5, using the non-parametric Mann-Whit-
ney test (SPSS), indicated that BR, BS, Bv1v3 and
BR(N283T) all had statistically significant higher infectiv-
ity than SPL, SB and SPL(T283N), as well as than Bv1v2
(except for Bv1v3).
For the anti-CD4 mAb inhibition data, non-linear regres-
sion analysis showed that all curves fitted well to the sig-
moidal dose-response model (R2 ≥ 0.92) and that the null
hypothesis of a single best fit curve for all data sets could
be rejected (F test, p < 0.0001). We then compared all pos-
sible pairs and found that dose-response curves for BR, BS,
Bv1v3 and BR(N283T) were statistically different from the
curves for SPL, SB, SPL(T283N) and Bv1v2, since the null
hypothesis of a single best fit curve for the two data sets
could be rejected (Table 2). The analysis provided as well
with estimated 50% inhibitory concentrations (IC50) and
95% confidence intervals that are shown in Table 3.
Surprisingly, the env clones obtained from genomic DNA
extracted from microglial cells infected with an isolate
recovered from brain tissue co-cultured with MDMs
(DS12, DS13 and DS17) [38,73,74] displayed a mixed
phenotype, since they all showed a similar ability than BR
to infect cells expressing low levels of CD4 but had a much
greater sensitivity, similar to that observed with SPL, to
inhibition of infection by the SK3 anti-CD4 mAb (Figure
2 and Tables 2 and 3; only DS17 is shown but the other
two clones had the same phenotype). In addition, the
mutant Env generated in the background of the DS17 env
clone, DS17(N283T), had an identical phenotype to the
parental DS17 Env in both CD4 dependence and sensitiv-
ity to anti-CD4 mAb. Thus, while some Env with a greater
capacity to utilize low levels of CD4 for infection may also
feature a high avidity for CD4 (as shown by the ability to
outcompete the presence of an anti-CD4 mAb), some
other Env may be able to acquire low CD4 dependence by
a different mechanism not involving an increased avidity
for CD4 in the context of the trimeric Env:CD4 interac-
tion.
Although it has been reported that brain-derived Env may
also have reduced CCR5 dependence and/or increased
affinity for CCR5, albeit in the absence of differences in
sensitivity to the CCR5 inhibitor TAK-779 [55], we did not
find such phenotypic differences in our initial characteri-
zation of these brain- and spleen-derived Env [54]. Con-
currently, we did not observe any difference in CCR5
dependence among the wild-type, chimeric and mutant
Env evaluated in this study. In addition, contrary to CD4,
CCR5 levels in microglia and macrophages seem to be
comparable to those in other target cells for HIV-1 such as
CD4+ T-cells [30,33,89,90], and therefore it may not be
surprising that acquisition of reduced CCR5 dependence
by neurotropic Env may occur less frequently than that of
low CD4 dependence.Retrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
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CD4 dependence and avidity of pseudotypes containing wild-type, chimeric and mutant Env Figure 2
CD4 dependence and avidity of pseudotypes containing wild-type, chimeric and mutant Env. Env-pseudotyped 
viruses were used to infect transiently-transfected QT6 cells expressing either low or high levels of CD4 and CCR5 (top) or 
HOS-CD4-CCR5 cells in the presence of the SK3 anti-CD4 mAb (bottom). BR, BS, Bv1v3 and BR(N283T) showed greater 
ability to infect cells expressing low levels of CD4 (low CD4 dependence) and were less sensitive to inhibition by the anti-CD4 
mAb SK3 than SPL, SB and SPL(T283N), while Bv1v2 had an intermediate phenotype. The brain isolate-derived DS17 Env and 
the DS17(N283T) mutant had a mixed phenotype with low CD4 dependence but high sensitivity to the anti-CD4 mAb. Aver-
age + standard error from 4 independent experiments (top) and data from a representative experiment repeated at least 4 
times with similar results (bottom) are shown.
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Fusogenicity
In addition to using single-round, Env-pseudotyped
viruses to test for the ability of various Env to mediate
infection, Env-mediated cell-to-cell fusion assays are also
commonly used to evaluate their ability to interact with
receptors and mediate fusion in the context of cell-cell
interaction, rather than virus-cell interaction. We evalu-
ated CD4 dependence and sensitivity to the SK3 anti-CD4
mAb with wild-type, chimeric and mutant Env using cell-
to-cell fusion and obtained similar results to those
described above with pseudotype infection (data not
shown), confirming similar functionality in both types of
assays. The presence of multinucleated giant cells is the
principal neuropathological finding of HIV-1 infection in
the brain and the hallmark of HIV-1 encephalitis [24-27],
and high fusion was found to be characteristic of the Env
of an in vitro microglia-adapted isolate [50,51] and of env
clones derived from brain tissues [54,55,57]. In addition,
Table 1: Analysis of the relative pseudotype infection in cells expressing low levels of CD4.
BS Bv1v3 Bv1v2 Br (N283T) Spl SB Spl (T283N) DS17 DS17 (N283T)
Br 0.670 0.462 0.019 0.831 0.019 0.020 0.021 0.394 0.394
BS 0.715 0.025 0.522 0.010 0.010 0.011 0.262 0.337
Bv1v3 0.144 0.584 0.018 0.049 0.027 0.465 0.715
Bv1v2 0.016 0.109 0.054 0.055 0.631 0.337
Br(N283T) 0.004 0.010 0.011 0.200 0.423
Spl 0.669 0.670 0.037 0.037
SB 0.767 0.087 0.054
Spl(T283N) 0.055 0.055
DS17 0.873
Significance (p) values were obtained with the non-parametric Mann-Whitney test for the comparison of the relative infection with the indicated 
pseudotypes in cells expressing low levels of CD4; p values below 0.05 were considered significant (shown in bold).
Table 2: Analysis of inhibition of pseudotype infection in the presence of anti-CD4 antibody.
BS Bv1v3 Bv1v2 Br (N283T) Spl SB Spl (T283N) DS17 DS17 (N283T)
Br 0.2363 0.8349 0.0032 0.3344 0.0005 0.0004 0.0027 <0.0001 <0.0001
BS 0.2286 0.0010 0.2638 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Bv1v3 0.0021 0.5091 <0.0001 0.0001 0.0010 <0.0001 <0.0001
Bv1v2 0.0472 0.0212 0.1048 0.1863 0.0002 0.0001
Br(N283T) 0.0008 0.0013 0.0064 <0.0001 <0.0001
Spl 0.1783 0.1787 0.7203 0.8227
SB 0.8959 0.0055 0.0066
Spl(T283N) 0.0067 0.0023
DS17 0.1487
Significance (p) values were obtained with an F test; p values below 0.05 were considered significant (shown in bold) an indicate rejection of the null 
hypothesis of a single best fit curve for both data sets.Retrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
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asparagine in position 362 in gp120's C3 region, which
has been found in a higher proportion of CCR5-using Env
derived from AIDS patients than from individuals with
asymptomatic infection, has been shown to contribute,
albeit in a strain-dependent manner, to increased
fusogenicity and higher sensitivity to an anti-CD4bs mAb,
perhaps by promoting greater exposure of the CD4bs and/
or stabilizing the CD4-bound Env conformation [91].
However, wild-type BR and SPL Env, as well as DS12,
DS13 and DS17, all have N362 and thus any difference in
fusogenicity will be due to other determinants.
Therefore, we decided to test the fusogenicity of wild-type,
chimeric and mutant Env in a cell-to-cell fusion assay in
which the co-cultivation of effector and target cells was
performed for 30–420 minutes, to obtain information
regarding the amount of fusion mediated by each Env at
every time point. Background-subtracted luciferase activ-
ity (used as reporter gene) data presented in Figure 3 dem-
onstrated that BR, BR(N283T), BS and Bv1v3 mediated
fusion more efficiently than SPL, SPL(T283N) and SB,
while Bv1v2, DS17, DS17(N283T) and BaL (a well-char-
acterized, macrophage-tropic Env [92] used as a control)
showed an intermediate level of fusion.
To analyze these results, we only considered the
fusogenicity data between 60–420 minutes, since this
assay is based on a reporter gene and there is of course a
delay between the completion of fusion and the produc-
tion of luciferase. However, this delay should be the same
for all Env, and differences observed in luciferase activity
should therefore reflect differences in fusogenicity, that is,
in the amount and rate of fusion mediated by each indi-
vidual Env. All curves fitted well to the exponential model
in non-linear regression analysis (R2 ≥ 0.96) and the null
hypothesis of a single best curve for all data sets could be
rejected (F test, p < 0.0001). As shown in Table 4, we esti-
mated the amount of time needed for each Env to cause
the luciferase activity in cell lysates to reach two arbitrary
thresholds, 1.0E+4 and 1.0E+5 RLU/second, and found
Table 3: IC50 values obtained in inhibition experimentsa.
SK3 anti-CD4 (ng/ml) T-1249 (nM) T-1249-BR (nM) BMS-378806 (nM) HNG-105 (μM)
Br 119 (58–246) 173 (129–230) 195 (157–298) 15 (9.4–23) 3.8 (2.2–6.5)
BS 79 (60–102) 140 (113–172) 155 (83–289) 20 (13–31) 1.8 (0.9–3.7)
Bv1v3 94 (55–158) 227 (110–468) 245 (156–387) 8.2 (5.7–12) 21 (12–36)
Bv1v2 22 (13–36) 224 (174–288) 155 (123–195) 4.8 (3.5–6.6) 48 (9.8–231)
Br(N283T) 60 (32–114) 166 (102–271) 221 (148–329) 13 (4.6–35) 7.2 (2.2–24)
Spl 5.7 (2.3–14) 37 (19–71) 27 (17–43) 1.8 (1.3–2.7) 16 (6.7–39)
SB 11 (6.4–18) 83 (53–129)b 41 (30–56)b 2.0 (1.2–3.5) 25 (12–50)
Sv1v3 n.d. n.d. n.d. 0.9 (0.6–1.3) n.d.
Sv1v2 n.d. n.d. n.d. 1.2 (0.7–2.2) n.d.
Spl(T283N) 11 (7.3–18) n.d. n.d. 0.9 (0.7–1.3) n.d.
DS17 5.4 (3.8–7.7) 210 (160–274)b 92 (73–116)b 41 (29–58) 4.1 (2.7–6.2)
DS17(N283T) 5.1 (4.0–6.4) 155 (119–202) 104 (72–150) 32 (24–41) 2.6 (1.0–6.6)
BaL n.d. 102 (85–122) 124 (103–149) 29 (15–59) 58 (14–241)
HxB n.d. n.d. n.d. 3.9 (2.8–5.4) 1.6 (0.7–3.6)
a Non-linear regression analysis of dose response curves generated for various viruses and inhibitors was performed with GraphPad Prism software; 
IC50 values are shown, with 95% confidence limits between parenthesis.
b SB and DS17 were the only Env that demonstrated statistically significant greater sensitivity to T-1249-BR than to parental T-1249 (F test, p < 0.05 
and p < 0.001, respectively).
n.d., not determined.Retrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
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that, in agreement with the differences in fusion efficiency
indicated above, BR, BR(N283T), BS and Bv1v3 were able
to reach these thresholds in a remarkably shorter time
than SPL, SPL(T283N) and SB, while again Bv1v2, DS17,
DS17(N283T) and BaL showed an intermediate pheno-
type. Similarly, the time needed for the luciferase activity
to increase from the lower to the higher threshold
reflected the higher fusogenic capacity of BR, BR(N283T),
BS and Bv1v3 when compared to SPL, SPL(T283N) and
SB, since the former required approximately half the time
than the later (Table 4). Therefore, in this group of wild-
type, chimeric and mutant Env high fusogenicity mostly
correlates with low CD4 dependence and high avidity for
CD4. However, DS17 and DS17(N283T) displayed a
mixed phenotype since they had intermediate fusogenic-
ity with low CD4 dependence but a lack of increased avid-
ity for CD4 (as indicated by the sensitivity to inhibition by
the anti-CD4 mAb).
Sensitivity to fusion inhibitors
We had previously described that the increase in
fusogenicity of brain-derived Env from this individual cor-
related with reduced sensitivity to the fusion inhibitor T-
1249 [54]. These clones from brain contained several con-
served amino acid differences in the HR2 region of gp41
with respect to those from the spleen, at positions with
various degrees of polymorphism. Although the high
fusogenicity of the BS and Bv1v3 but not the SB chimeras
seems to indicate that these changes in gp41 do not deter-
mine the fusogenicity observed, it would still be possible
that they play a role in the reduced sensitivity to fusion
inhibitors, e.g., by promoting an improved interaction
between HR1 and HR2 that might lead to a more efficient
fusion process and/or reduced sensitivity to inhibitors.
For this reason, we wanted to test whether fusion inhibi-
tors-derived peptides containing all or some of these con-
served changes found in brain-derived gp41 could
function as inhibitors of the fusion process with similar or
greater potency than T-20 and T-1249. Thus, T-20 (also
known as Enfuvirtide) and T-1249, as well as derived pep-
tides T-20-BR (YTNLIYNLIEKSQNQQEMNEQELLKLDT-
WASLWNWF) and T-1249-BR
(WQEWEQKITALLEQAQIQQEMNEQELQKLDT-
WASLWEWF) that contain amino acid changes present in
the HR2 region of H0002GH brain-derived Env (shown in
bold), were synthesized and used for inhibition of infec-
tion by pseudotypes containing wild-type, chimeric and
mutant Env. All pseudotypes showed very similar inhibi-
tion by the less potent T-20 and derived peptide T-20-BR
(data not shown). However, inhibition experiments with
T-1249 and T-1249-BR (Figure 4) demonstrated that pseu-
dotypes with BR, BS, Bv1v3, Bv1v2 and BR(N283T) Env,
as well as those with DS17, DS17(N283T) and BaL, were
less sensitive than those with SPL and SB Env. Non-linear
regression analysis and estimation of IC50s confirmed the
differences in sensitivity (Table 3). Therefore, these data
suggested that the gp41 subunit of the brain-derived Env
is not responsible for the reduced sensitivity to fusion
inhibitors. On the contrary, it seems that the gp120 subu-
nit of the brain Env, and specifically the regions involved
in conferring low CD4 dependence, are also involved in
determining the increased fusogenicity and reduced sensi-
tivity to fusion inhibitors, at least in these Env genetic
backgrounds.
In addition, most pseudotypes showed similar sensitivity
to both T-1249 and T-1249-BR, suggesting that the fusion
inhibitor modified with amino acids from brain Env's
HR2 region does not usually have higher efficiency than
parental T-1249. However, as shown in Table 3, the SB
and DS17 pseudotypes had statistically significant greater
sensitivity to T-1249-BR than to T-1249, since an F test
performed as part of non-linear regression analysis
rejected the null hypothesis of a single best fit curve for
Fusogenicity of wild-type, chimeric and mutant Env Figure 3
Fusogenicity of wild-type, chimeric and mutant Env. 
Cell-to-cell fusion assays of Env-expressing effector QT6 
cells and target QT6 cells transiently transfected for the 
expression of high levels of CD4 and CCR5 were performed 
to test fusogenicity. Co-culture of effector and target cells 
for 30–420 minutes showed that BR, BR(N283T), BS and 
Bv1v3 fused more efficiently than SPL, SPL(T283N) and SB, 
while Bv1v2, DS17, DS17(N283T) and BaL showed an inter-
mediate phenotype. Data shown is the average background-
subtracted, actual relative light units (RLU) per second from 
3 independent experiments.
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both inhibitors with each pseudotype (p < 0.05 and p <
0.001, for SB and DS17, respectively). Thus, it is interest-
ing that only in the context of the SB chimera (but not
with the wild-type brain-derived Env) and DS17, T-1249-
BR seemed to show a slightly, but significant, higher
potency than parental T-1249. Since the SB chimera does
not have low CD4 dependence, high avidity for CD4 or
increased fusogenicity, but does contain the brain gp41
subunit in which the T-1249-BR sequence is based upon,
it is possible that only in this context of limited efficiency
in the interaction with CD4 and limited fusogenicity, T-
1249-BR will be able to demonstrate a greater efficiency
than T-1249 at blocking fusion mediated by the brain-
derived gp41.
Interaction between HR1- and HR2-derived peptides
In addition, we developed a surface plasmon resonance
assay to evaluate whether the modified T-1249-BR might
differ from parental T-1249 in the interaction with the
HR1 region in gp41. In this assay, a biotinylated, HR1-
derived peptide (N40) was synthesized and immobilized
onto the surface of a streptavidin-coated chip to evaluate
binding of the HR2-derived T-1249 and T-1249-BR using
a Biacore® 3000 optical biosensor. Under the experimental
conditions outlined in Materials and Methods, and over a
concentration range of 81–650 nM, both HR2-derived
peptides interacted in a similar manner with the immobi-
lized HR1-derived peptide resulting in an almost identical
amount of mass bound at the sensor surface (1 response
unit = 1 pg/mm2). Moreover, the interaction was specific
since no binding was observed to the immobilized, bioti-
nylated N40scr, scramble peptide (data not shown). Thus,
we did not find a qualitatively appreciable difference
between the two peptides.
In summary, the amino acid changes found in the HR2
region of gp41 in brain-derived Env from H0002GH did
not seem to affect the interaction between HR2- and HR1-
derived peptides in biosensor experiments, and did not
seem to contribute to the increased fusogenicity or to the
reduced sensitivity to fusion inhibitors, as compared to
the spleen-derived Env. Furthermore, low CD4 depend-
ence and reduced sensitivity to the anti-CD4 mAb, and
increased fusogenicity and reduced sensitivity to peptide
fusion inhibitors seem to be determined by the same viral
determinants in gp120.
Sensitivity to the entry inhibitors BMS-378806 and HNG-
105
To gain additional information regarding the phenotypes
of Env with low CD4 dependence and increased
fusogenicity, we tested the sensitivity of pseudotype infec-
tion to the gp120-targeted entry inhibitors BMS-378806
and HNG-105. The mechanism of action of the small
Table 4: Analysis of Env-mediated fusogenicitya.
Log10 [Ymax] (95% confidence limit) Time to reach 1.0E+4 RLU/secb Time to reach 1.0E+5 RLU/secb Difference
Br 5.94 (5.76–6.12) 99 163 64
Spl 5.43 (5.01–5.85) 161 307 146
BS 5.83 (5.65–6.01) 106 178 72
SB 5.59 (5.49–5.70) 175 312 137
Br(N283T) 5.93 (5.74–6.12) 104 171 67
Spl(T283N) 5.50 (5.12–5.88) 175 323 148
Bv1v3 5.93 (5.71–6.14) 109 180 71
Bv1v2 5.62 (5.43–5.81) 137 243 106
DS17 5.65 (5.44–5.86) 125 220 95
DS17(N283T) 5.61 (5.32–5.89) 121 215 94
BaL 5.70 (5.51–5.89) 122 211 89
aNon-linear regression analysis was performed using an exponential model (Ymax, estimated maximal response in RLU/second) with background-
subtracted data comprising 60–420 minutes after initiation of co-culture.
bEstimated time is expressed in minutes.Retrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
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Sensitivity of pseudotypes to fusion inhibitors Figure 4
Sensitivity of pseudotypes to fusion inhibitors. Pseudotypes were incubated for 1 h. at 37°C with fusion inhibitors T-
1249 (A) and T-1249-BR (a peptide that contains amino acid residues conserved in brain but absent in spleen derived Env of 
one individual) (B), and then the mixture was used to infect HOS-CD4-CCR5 cells. Pseudotypes containing BR, BS, Bv1v3, 
Bv1v2 and BR(N283T) Env were significantly less sensitive to T-1249 and T-1249-BR than those with SPL and SB Env. Data 
from a representative experiment repeated at least 4 times with similar results are shown.
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molecule BMS-378806 [77,78] remains controversial; it
has been suggested that it suppresses infection by inhibi-
tion of CD4 binding [79,80] and/or affecting the CD4-
induced conformational re-arrangement of gp120 and
gp41 [81,82]. As shown in Figure 5 and Table 5, pseudo-
types containing the BR, BR(N283T), BS and Bv1v3 Env
were significantly less sensitive to inhibition by BMS-
378806 than those with SPL, SPL(T283N), SB, Sv1v3 or
Sv1v2 (as demonstrated by non-linear regression analysis
with a sigmoidal dose-response model and estimation of
IC50 values), while Bv1v2 displayed again an intermediate
sensitivity. Estimated IC50 values are shown in Table 3.
This pattern of sensitivity seems to indicate that the low
CD4 dependence either modulates or correlates with the
sensitivity of various Env to this entry inhibitor. One
potential mechanism could be by accelerating the entry
process and reducing the time when the Env remains sen-
sitive to inhibition. Alternatively, the low CD4 depend-
ence may be acquired through an altered gp120
conformation that might mainly affect the positioning of
the variable loops V1/V2 and V3, perhaps resulting in
diminished interaction with BMS-378806. In fact, the V1/
V2 variable loop and N-linked carbohydrates on the V1/
V2 stem have been shown to influence sensitivity to this
small molecule [82]. This latter possibility would also be
in agreement with the altered gp120 conformation that
was proposed as the mechanism of acquisition of low
CD4 dependence for the Env of the previously character-
ized  in vitro microglia-adapted isolate, HIV-1Bori-15
[49,50,52].
HNG-105 is an entry inhibitor that, similar to its parental
peptide 12p1 [85,86], seems to work by a novel allosteric
mechanism that involves interaction with a site in gp120
different than the CD4 or co-receptor binding sites, but
results in reduced affinity of gp120 for both receptors
[84]. We recently reported that a broad range of sensitivi-
ties to HNG-105 could be found not only among Env
from various subtypes, but also within subtype B [83],
and even between the Env of the highly related parental
HIV-1Bori  and  in vitro microglia-adapted HIV-1Bori-15,
which only differ in 8 amino acids [50]. However, these
Table 5: Analysis of inhibition of pseudotype infection by BMS-378806
Spl BS SB Bv1v3 Bv1v2 Sv1v3 Sv1v2 Br 
(N283T)
Spl 
(T283N)
DS17 DS17 
(N283T)
BaL HxB
Br <0.001 0.598 <0.001 0.044 <0.001 <0.001 0.002 0.620 <0.001 0.003 0.107 0.456 0.002
Spl <0.001 0.916 <0.001 0.001 0.239 0.521 <0.001 0.162 <0.001 <0.001 <0.001 0.010
BS <0.001 0.003 <0.001 <0.001 <0.001 0.392 <0.001 0.040 0.422 0.688 <0.001
SB <0.001 0.039 0.390 0.610 0.002 0.323 <0.001 <0.001 0.003 0.090
Bv1v3 <0.001 0.001 0.002 0.608 <0.001 <0.001 <0.001 0.047 0.044
Bv1v2 <0.001 0.002 0.014 <0.001 <0.001 <0.001 <0.001 0.006
Sv1v3 0.456 0.044 0.115 <0.001 <0.001 <0.001 <0.001
Sv1v2 0.093 0.196 <0.001 <0.001 <0.001 0.003
Br
(N283T)
0.059 0.016 0.193 0.722 0.141
Spl
(T283N)
<0.001 <0.001 <0.001 <0.001
DS17 0.457 0.368 <0.001
DS17
(N283T)
0.338 <0.001
BaL <0.001
Significance (p) values were obtained with an F test; p values below 0.05 were considered significant (shown in bold) an indicate rejection of the null 
hypothesis of a single best fit curve for both data sets.Retrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
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differences in sensitivity to inhibition of infection in the
context of pseudotyped viruses did not seem to correlate
with changes in direct binding affinity between the solu-
ble monomeric gp120s and HNG-105 in biosensor exper-
iments [83]. Therefore, it is possible that conformational
masking of the HNG-105 binding site, which is thought
to reside within the gp120 inner domain, in the context of
the viral trimers present in the surface of virions could
play a principal role in modulating the sensitivity to
HNG-105. We thus evaluated wild-type, chimeric and
mutant Env and found that BR, BS, BR(N283T), DS17 and
DS17(N283T) had greater sensitivity to inhibition than
SPL, SB, Bv1v3, Bv1v2 and BaL (Figure 6). Surprisingly,
the sensitivity to HNG-105 of Bv1v3 and Bv1v2 is more
similar to that of SPL rather than BR, suggesting that the
conformational alterations may have differential effects
on the accessibility of various inhibitors to their binding
sites, and that other regions in the spleen Env may deter-
mine the reduced sensitivity to HNG-105. A potential
binding site for 12p1 and HNG-105 within gp120 has
been identified using mutated Env in pseudotype infec-
tion assays; when mutated to alanine, residues K97, E102
and R476 seemed to confer a reduced sensitivity to inhibi-
tion by these peptides [85], and it was hypothesized that
this may occur by decreasing the affinity of the peptides
for the Env complex. However, whether these residues
actually represent or belong to a bona fide binding site or
not, remains to be elucidated. In addition, all of these
foot-print residues are present in both wild-type BR and
SPL Env. Thus, we hypothesize that the differences in sen-
sitivity to inhibition of entry by HNG-105 may be caused
by conformational variations between the Env, rather
than diminished interaction with the inhibitor. These
conformational variations in the context of the Env trim-
ers could restrict the accessibility of HNG-105 to its bind-
ing site, probably resulting in the altered sensitivity to its
inhibitory effect.
In this regard, it has been shown in a very recent paper by
Liu et al [93] that changes associated with CD4-binding
seem to open up the trimeric Env structure significantly,
and this occurs primarily by conformational changes
affecting the variable domains. In the context of the sensi-
tivity to HNG-105, a slightly more "triggered" conforma-
tion in the BR Env might allow access of the peptide to the
inner domain, whereas with the SPL Env, the more
"closed" and compact structure would not allow it, per-
haps resulting in the differences in sensitivity that we have
observed. Considering the dynamism and flexibility of
gp120, this could be explained by the possibility that a
gp120 that is further away from the CD4-bound confor-
Sensitivity of pseudotypes to the entry inhibitor BMS-378806 Figure 5
Sensitivity of pseudotypes to the entry inhibitor 
BMS-378806. Pseudotypes were incubated for 1 h. at 37°C 
with the gp120-targeted small molecule BMS-378806 and 
then the mixture was added to HOS-CD4-CCR5 cells. Pseu-
dotypes containing BR, BR(N283T), BS and Bv1v3 Env were 
significantly less sensitive than those with SPL, SPL(T283N), 
SB, Sv1v3 or Sv1v2, while Bv1v2 displayed an intermediate 
sensitivity. DS17 and DS17(N283T) did not differ between 
them but showed reduced sensitivity to BMS-378806 as com-
pared to the BR and Env with related phenotype. Data from 
a representative experiment repeated at least 4 times with 
similar results are shown.
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Sensitivity of pseudotypes to the entry inhibitor HNG-105 Figure 6
Sensitivity of pseudotypes to the entry inhibitor 
HNG-105. Pseudotypes were incubated for 1 h. at 37°C 
with the gp120-targeted short peptide HNG-105 and then 
the mixture was added to HOS-CD4-CCR5 cells. Pseudo-
types containing BR, BR(N283T) and BS Env were signifi-
cantly more sensitive than those with SPL, SB, Bv1v3 or 
Bv1v2. DS17 and DS17(N283T) did not differ between them 
and showed similar sensitivity to HNG-105 than BR, 
BR(N283T) and BS. Data from a representative experiment 
repeated at least 3 times with similar results are shown.
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mation would sample CD4-bound conformations less fre-
quently than another gp120 that is closer or partially
triggered.
Macrophage tropism
In order to evaluate whether a relationship between the
degree of low CD4 dependence and/or increased
fusogenicity of wild-type, chimeric and mutant Env, and
their ability to mediate infection of primary macrophages
(or macrophage tropism) could be established, MDMs
were infected with equivalent amounts of pseudotype
stocks. HOS-CD4-CCR5 cells were infected in parallel.
After 2–3 days, the extent of infection was measured by
luciferase activity in cell lysates. As shown in Figure 7,
HOS-CD4-CCR5 cells were infected to a similar extent by
all pseudotypes, with luciferase activity at least 1000-fold
above background levels (mock infection refers to super-
natants containing viral particles lacking Env produced by
cells co-transfected with the Env-deficient luciferase back-
bone and an empty vector). By contrast, only those pseu-
dotypes with low CD4-dependent Env showed the ability
to infect MDMs, although with various efficiencies. Infec-
tion with wild-type BR and BS chimera resulted in luci-
ferase activities 1000-fold above mock infection, and
greater than a 100-fold increase was observed with the
Bv1v3 chimera, the BR(N283T) mutant and the DS17 and
DS17(N283T). The Bv1v2 chimera containing the V1/V2
region of the brain Env in the context of the spleen Env
mediated infection of macrophages to a lower extent than
BR or Bv1v3, although luciferase levels were still 20-fold
above background, indicating that brain Env's V3 region
plays a role, together with the V1/V2, in increasing macro-
phage tropism. However, the Sv1v2 chimera containing
the V1/V2 region from SPL and the remaining of the Env
from BR (including the V3 loop) failed to mediate any
infection of macrophages suggesting that, by itself, the
brain Env's V3 region does not confer macrophage tro-
pism.
Therefore, low CD4 dependence seems to correlate not
only with fusogenicity and with the sensitivity to fusion
and other entry inhibitors, but also with the macrophage
tropism of Env. This is in agreement with recent work by
Thomas et al. [57] reporting that Env conferring macro-
phage tropism display low CD4 dependence and higher
efficiency of fusion. Our results are also comparable to
those recently published by Peters et al. [56] in that there
is a relationship between macrophage tropism and sensi-
tivity to certain entry inhibitors. Similar to us, they found
that decreasing sensitivity to an anti-CD4 mAb and to
BMS-378806 correlated with increasing macrophage tro-
pism. However, they did not find a reduced sensitivity of
macrophage-tropic Env to the fusion inhibitor T-20 (in
fact, a trend towards increased sensitivity to T-20 with
increasing macrophage tropism was observed), while in
our study, we did find that macrophage-tropic Env had
significantly lower sensitivity to the more potent, second-
generation fusion inhibitor T-1249 (but not to T-20), than
non-macrophage-tropic Env. It is possible that this dis-
crepancy could be due to the difference in potency
between the two fusion inhibitors.
Modeling studies
Contrary to Dunfee et al. [53], we did not observe a role
for N283 in determining macrophage tropism in these
particular Env backgrounds, since the T283N change did
not confer macrophage tropism to the SPL Env and the
N283T change did not alter the macrophage tropism of
the BR or DS17 Env. Therefore, since these changes did
not affect macrophage tropism or CD4 dependence (as
described above), we performed modeling studies using
Pseudotype infection of HOS-CD4-CCR5 cells (top) and  monocyte-derived macrophages (bottom) Figure 7
Pseudotype infection of HOS-CD4-CCR5 cells (top) 
and monocyte-derived macrophages (bottom). Pseu-
dotypes containing wild-type, chimeric and mutant Env that 
had shown low CD4 dependence and high avidity for CD4, 
as well as reduced sensitivity to fusion inhibitors and BMS-
378806, showed statistically significant greater macrophage 
tropism than those without low CD4 dependence and less 
avidity for CD4. Results shown are the mean relative light 
units (RLU) per second ± standard error of 3 independent 
experiments (each performed at least in triplicate).
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the Swiss Model Server http://swissmodel.expasy.org/
SWISS-MODEL.html[94] to gain an insight into the
potential differential effects of N or T at position 283 in
gp120's C2 region among the various Env utilized in this
study. The consensus amino acid of subtype B Env at posi-
tion 283 is T, and this is the residue found in the HIV-1JR-
FL gp120, whose structure in complex to CD4 and the
CCR5 surrogate 17b mAb is shown in Figure 8A (2B4C;
visualized with Pymol v0.99 [DeLano Scientific]; CD4 is
shown in green) [95]. As reported before in Dunfee et al.
[53], substitution of T for N in this structure results in an
increased potential for a hydrogen bond contact with res-
idue Q40 (in yellow) of CD4, since the distance is reduced
from 3.7 to 2.4Å (Figure 8B), while the maximum dis-
tance between a donor-acceptor pair to form a hydrogen
bond is usually considered to be 3.3Å, approximately. We
modeled the structure of DS17 based on the crystal of
HIV-1JR-FL gp120, and found that both wild-type N283
and mutant T283 appeared to be at a distance from Q40
that suggests that the formation of a hydrogen bond con-
tact is unlikely (Figures 8C and 8D). Unfortunately, the
BR gp120 could not be modeled with any of the reported
gp120 crystal structures, while the SPL gp120 did return a
good model based on the HIV-1YU-2 gp120 crystal struc-
ture (1G9N) [10]. This model suggested that both wild-
type T283 and mutant N283 would be at a distance from
Q40 that would allow the formation of a hydrogen bond
(Figures 8E and 8F), although it would be more likely
with N283 than with T283 since the distance is notably
reduced. However, as reported above, we did not find any
difference in CD4 dependence or macrophage tropism
between the wild-type and mutant BR, SPL and DS17 Env,
therefore confirming that the role of N283 in these phe-
notypes is highly context-dependent.
Modeling studies are always to some extent speculative
since they are based on previous crystal structure data and
sequence information. However, we evaluated the relia-
bility of these molecular models using Verify3D http://
nihserver.mbi.ucla.edu/Verify_3D/, which determines the
goodness of a model based on an available structure [96-
99]. This analysis has confirmed the goodness of our
models for DS17 and SPL Env, since for both we obtained
scores greater than zero throughout gp120 on the
Verify3D plot. Regions of bad fitting and loop regions
tend to score zero or close to zero, and in fact a large pro-
portion of BR gp120 (corresponding to the structured
inner domain), which we could not model, had values
close to zero with the published gp120 crystal structures.
Therefore, we are confident with the models presented
above.
Conclusion
We had previously found that brain-derived Env from an
individual with HIV-1 encephalitis have lower CD4 but
not CCR5 dependence, increased fusogenicity and
reduced sensitivity to inhibition by anti-CD4 mAbs and
the fusion inhibitor T-1249, but not by the CCR5 antago-
nist TAK-779, than their splenic counterparts [54]. We
hypothesized that the brain gp120 would contain the
determinants for low CD4 dependence and higher avidity
for CD4, while gp41 could likely play a role in the
increased fusogenicity and reduced sensitivity to fusion
inhibitors. In the present study, we have used chimeric
and mutant Env and have identified that the V1-V3 region
of the brain gp120 contains the determinants not only for
low CD4 dependence, but also for the increased
fusogenicity, enhanced macrophage tropism and reduced
sensitivity to fusion inhibitors and the small molecule
BMS-378806. Macrophage tropism had already been
linked to low CD4 dependence and increased fusogenicity
[31,39,41,53,55,57,67] and our study identified the spe-
cific gp120 region from a brain-derived, CCR5-using,
macrophage-tropic Env conferring these phenotypes. The
chimera containing the V1/V2 region of the brain-derived
Env in the context of the spleen Env displayed an interme-
diate phenotype with reduced low CD4 dependence, mac-
rophage tropism and fusogenicity, as compared to BR, but
still different from SPL. This confirms that brain gp120's
V3 region plays a role in the macrophage tropism of this
Env, but also suggests that it is the V1/V2 region the main
determinant for these phenotypes. However, regarding
the sensitivity to entry inhibitors, although there is a clear
relationship between macrophage tropism and dimin-
ished sensitivity to BMS-378806 (similarly to Peters et al.
[56]), this is not the case with HNG-105, since some mac-
rophage-tropic Env (Bv1v3, Bv1v2, BaL) show reduced
sensitivity similar to the non-macrophage tropic Env SPL
and SB, and quite different from the other macrophage-
tropic Env, BR, BR(N283T), BS, DS17 and DS17(N283T).
This could relate to the proposed allosteric mechanism of
action of HNG-105.
Potentially, differences in the level of expression between
wild-type, chimeric and mutant Env could have an impact
on the phenotypes observed; however, it is not likely that
this is the case since luciferase activity in cell-to-cell fusion
assays was always between 100 and 1000-fold higher than
the background levels, and pseudotype infection of HOS-
CD4-CCR5 cells showed limited variability between pseu-
dotype stocks but always remained at least 1000-fold
higher than background levels. In addition, the fact that
many pseudotypes display an opposite sensitivity to
HNG-105 than to anti-CD4 mAb, BMS-378806 and
fusion inhibitors supports the specificity of the results.
Diminished sensitivity to co-receptor and fusion inhibi-
tors has been shown to correlate with higher affinity of
gp120 for the co-receptor molecule CCR5 and with faster
fusion kinetics [100,101]. In this set of Env, reduced sen-Retrovirology 2008, 5:89 http://www.retrovirology.com/content/5/1/89
Page 18 of 22
(page number not for citation purposes)
Modeling the potential role of N283/T283 in various Env for gp120:CD4 interaction Figure 8
Modeling the potential role of N283/T283 in various Env for gp120:CD4 interaction. Swiss PDB Viewer was used to 
change T283 (A) to N283 (B) in the HIV-1JR-FL gp120 crystal structure (2B4C) [95], as previously described [53]; potential 
hydrogen bonds are indicated by dotted lines and the estimated distance is shown, suggesting a greater likelihood for formation 
of a hydrogen bond with Q40 (shown in yellow) in CD4 (green) for N283 than for T283, in the HIV-1JR-FL gp120 background. 
DS17 and DS17(N283T) Env were modeled based on the HIV-1JR-FL gp120 crystal structure (C and D, respectively) using the 
Swiss Model Server, and the models showed that the distance between T283 and Q40 would be shorter than between N283 
and Q40, although both would be larger than what it is usually accepted for the formation of a hydrogen bond (3.3Å). Finally, 
the SPL and SPL(T283N) Env were best modeled based on the HIV-1YU-2 gp120 crystal structure (E and F, respectively), and 
the models showed that both could potential make hydrogen bond contacts with Q40 in CD4, although the shorter distance in 
SPL(T283N) would suggest a greater likelihood for this to occur for mutated N283 than for wild-type T283. The brain-derived 
Env did not result in a good model with any of the published gp120 crystal structures.
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sitivity to T-1249 appears to correlate with lower CD4
dependence, increased fusogenicity and enhanced macro-
phage tropism, but not with a difference in the interaction
with CCR5. Resistance to fusion inhibitors is primarily
acquired both in vitro and in vivo through mutations in
HR1 and the association between reduced sensitivity and
mutations in HR2 has rarely been reported, and always in
the presence of additional mutations within HR1
[102,103]. While there were no amino acid differences in
the HR1 region of gp41e between brain and spleen clones,
HR2 contained several amino acid changes which
involved residues that can be considered polymorphic
(moderately to highly variable). Thus, it was possible that
the conserved amino acid sequence in the HR2 region of
brain Env could result in an alteration/improvement of
the interaction between HR2 and HR1, potentially
increasing the fusogenicity of brain-derived Env and mak-
ing the fusion process more resistant to the action of
fusion inhibitors. This could be of great relevance since it
might relate to the frequent finding of multinucleated
giant cells in the CNS (while they are absent in most other
tissues in vivo) and to the potential role of Env-mediated
cell-to-cell fusion of infected and uninfected cells in the
development of HIV encephalitis and the onset of neuro-
degeneration. Our results however demonstrate that, at
least in these Env backgrounds, the determinants for
increased fusogenicity and reduced sensitivity to fusion
inhibitors lie in gp120 and overlap with those conferring
low CD4 dependence, increased avidity for CD4 and
enhanced macrophage tropism. It is possible that the
genetic changes resulting in an altered Env conformation
that confers lower CD4 dependence, higher avidity for
CD4 and increased fusogenicity, may also affect the inter-
action with certain, but not all, entry inhibitors, with the
difference potentially being on changes on the accessibil-
ity of the key residues that interact with those inhibitors
due to the conformational alterations.
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